Stay updated on Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial

Sign up to get notified when there's something new on the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    A site-wide banner announces an NIH terminology transition, stating that federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” and linking to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-24T22:23:27.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The footer’s site revision identifier advances from v3.7.1 to v3.7.2, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-17T22:18:23.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The footer site revision changed from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-10T22:17:20.000Z thumbnail image
  4. Check
    36 days ago
    Change Detected
    Summary
    Access to the study page now returns a 403 Forbidden error, replacing the previously visible content with a basic error page. This indicates the page is currently blocked or unavailable, rather than a substantive update to the study information.
    Difference
    19%
    Check dated 2026-09-19T20:08:35.000Z thumbnail image
  5. Check
    57 days ago
    Change Detected
    Summary
    The page revision was updated from v3.6.5 to v3.6.6, indicating a minor update to the page’s template or content. This change does not modify the study details or user-facing information.
    Difference
    0.1%
    Check dated 2026-08-29T19:08:15.000Z thumbnail image
  6. Check
    78 days ago
    Change Detected
    Summary
    The page now shows a new site revision tag (v3.6.5) replacing the previous revision tag (v3.6.4), indicating a minor backend/UI update.
    Difference
    0.1%
    Check dated 2026-08-08T22:33:43.000Z thumbnail image

Stay in the know with updates to Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page.